Celiac disease (CD) is a known risk factor for osteoporosis and fractures. The prevalence of CD in patients with a recent fracture is unknown. We therefore systematically screened patients at a fracture liaison service (FLS) to study the prevalence of CD. Patients with a recent fracture aged ≥ 50 years were invited to VieCuri Medical Center’s FLS. In FLS attendees, bone mineral density (BMD) and laboratory evaluation for metabolic bone disorders and serological screening for CD was systematically evaluated. If serologic testing for CD was positive, duodenal biopsies were performed to confirm the diagnosis CD. Data were collected in 1042 consecutive FLS attendees. Median age was 66 years (Interquartile range (IQR) 15), 27.6% had a major and 6.9% a hip fracture, 26.4% had osteoporosis and 50.8% osteopenia. Prevalent vertebral fractures were found in 29.1%. CD was already diagnosed in two patients (0.19%), one still had a positive serology. Three other patients (0.29%) had a positive serology for CD (one with gastro-intestinal complaints). In two of them, CD was confirmed by duodenal histology (0.19%) and one refused further evaluation. The prevalence of biopsy-proven CD was therefore 0.38% (4/1042) of which 0.19% (2/1042) was newly diagnosed. The prevalence of CD in patients with a recent fracture at the FLS was 0.38% and within the range of reported prevalences in the Western-European population (0.33–1.5%). Newly diagnosed CD was only found in 0.19%. Therefore, standard screening for CD in FLS patients is not recommended.

腹腔疾病（CD）是骨质疏松症和骨折的已知危险因素。近期骨折患者中CD的患病率尚不清楚。因此，我们对骨折联络处（FLS）的患者进行系统筛查，以研究CD的患病率。最近有≥50岁骨折的患者被邀请到VieCuri Medical Center的FLS。在FLS与会者中，系统地评估了骨矿物质密度（BMD）和代谢性骨疾病的实验室评估以及CD的血清学筛查。如果CD的血清学检查呈阳性，则进行十二指肠活检以确诊CD。连续1042名FLS参与者收集了数据。中位年龄为66岁（四分位间距（IQR）15），其中严重骨折为27.6％，髋部骨折为6.9％，骨质疏松症为26.4％，骨质减少为50.8％。发现椎骨骨折的比例为29.1％。已在两名患者中诊断出CD（0.19％），其中一名仍呈阳性。其他三名患者（0.29％）的CD血清学呈阳性（一名患有肠胃不适）。其中两例经十二指肠组织学检查证实为CD（0.19％），其中一例拒绝进一步评估。因此，活检证实的CD患病率为0.38％（4/1042），其中新诊断为0.19％（2/1042）。FLS近期骨折患者的CD患病率为0.38％，并且在西欧人群的报道患病率范围内（0.33-1.5％）。新发现的CD仅占0.19％。因此，不建议对FLS患者进行CD的标准筛查。29％的人CD血清学呈阳性（一位患有肠胃不适）。其中两例经十二指肠组织学检查证实为CD（0.19％），其中一例拒绝进一步评估。因此，活检证实的CD患病率为0.38％（4/1042），其中新诊断为0.19％（2/1042）。FLS近期骨折患者的CD患病率为0.38％，在西欧人群的报道患病率范围内（0.33-1.5％）。新发现的CD仅占0.19％。因此，不建议对FLS患者进行CD的标准筛查。29％的人CD血清学呈阳性（一位患有肠胃不适）。其中两例经十二指肠组织学检查证实为CD（0.19％），其中一例拒绝进一步评估。因此，活检证实的CD患病率为0.38％（4/1042），其中新诊断为0.19％（2/1042）。FLS近期骨折患者的CD患病率为0.38％，并且在西欧人群的报道患病率范围内（0.33-1.5％）。新发现的CD仅占0.19％。因此，不建议对FLS患者进行CD的标准筛查。FLS近期骨折患者的CD患病率为0.38％，并且在西欧人群的报道患病率范围内（0.33-1.5％）。新发现的CD仅占0.19％。因此，不建议对FLS患者进行CD的标准筛查。在FLS最近骨折的患者中CD的患病率为0.38％，并且在西欧人群的报道患病率范围内（0.33-1.5％）。新发现的CD仅占0.19％。因此，不建议对FLS患者进行CD的标准筛查。